Search for Clinical Trial Results
Polyomavirus Infections - 25 Studies Found
Status | Study |
Recruiting |
Study Name: Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation Condition: Merkel Cell Carcinoma Date: 2014-06-20 Interventions: Drug: Ipilimumab adjuvant treatment of completely resected Merkel cell carcinoma |
Recruiting |
Study Name: Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Condition: Carcinoma, Merkel Cell Date: 2014-06-02 Interventions: Drug: Avelumab Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour in |
Recruiting |
Study Name: F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Date: 2014-01-31 Interventions:
|
Active, not recruiting |
Study Name: A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Date: 2014-01-10 Interventions: Biological: GLA-SE Glucopyranosyl Lipid A in Stable Emulsion |
Withdrawn |
Study Name: Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Date: 2013-07-28 Interventions: Drug: Ipilimumab Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is comm |
Terminated |
Study Name: Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Condition:
Date: 2012-12-27 Interventions:
|
Completed |
Study Name: IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer Condition: Merkel Cell Carcinoma Date: 2011-09-23 Interventions:
|
Active, not recruiting |
Study Name: Merkel Positron Emission Tomography (PET) Protocol Condition: Merkel Cell Carcinoma Date: 2009-11-12 Interventions:
|
Recruiting |
Study Name: Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Condition:
Date: 2017-03-01 Interventions:
|
Active, not recruiting |
Study Name: Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Condition:
Date: 2013-12-19 Interventions: Drug: Cabozantinib Cabozantinib 60 mg Oral Daily 28 days (4 weeks) |